Open AccessPreoperatively administered ramosetron oral disintegrating tablets for preventing nausea and vomiting associated with patient-controlled analgesia in breast cancer patients
Author(s) -
Heon-Jin Lee,
Jae Young Kwon,
Sang Chul Shin,
CheolHee Kim,
Seung Hoon Baek,
Seung Kug Baik,
H.-K. Kim,
K.-H. Kim
Publication year - 2008
Publication title -
european journal of anaesthesiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.445
H-Index - 76
eISSN - 1365-2346
pISSN - 0265-0215
DOI - 10.1017/s0265021508004262
Subject(s) - medicine , nausea , vomiting , antiemetic , anesthesia , postoperative nausea and vomiting , breast cancer , adverse effect , surgery , cancer
The purpose of this study was to investigate the acceptability and therapeutic efficacy of a preoperative single administration of long-acting 5-hydroxytryptamine type 3 (5-HT 3) receptor antagonist in an orally disintegrating tablet formulation, ramosetron, in breast cancer patients.